Blocking NR4A1 to slow down colorectal cancer and boost immune response
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
This study is looking at how a new type of medicine can help slow down the growth of colorectal cancer and boost the body's ability to fight it, with the hope of finding better treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11003348 on NIH RePORTER |
What this research studies
This research investigates how NR4A1 antagonists can inhibit the growth of colorectal cancer cells while enhancing the body's immune surveillance against these tumors. The approach involves testing these antagonists in various models to understand their effectiveness in slowing cancer progression and improving treatment outcomes. Patients may benefit from new therapeutic strategies that could be integrated into existing treatment regimens for colorectal cancer. The study aims to identify how these antagonists can work alongside current therapies to provide a more comprehensive treatment plan.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with colorectal cancer, particularly those with advanced stages of the disease.
Not a fit: Patients with early-stage colorectal cancer or those without a diagnosis of colorectal cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for colorectal cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
College Station, United States
- Texas A&m University — College Station, United States (Active)
Researchers
- Principal investigator: Safe, Stephen H. — Texas A&m University
- Study coordinator: Safe, Stephen H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.